NeoStem, Inc. (NBS) announced a collaboration with ImmuneRegen Biosciences, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS). NeoStem will investigate whether Homspera, ImmuneRegen’s lead product, will enhance stem cell activity when used in combination with NBS’s VSEL technology.
NeoStem is engaged in the business of developing stem cell therapies, pursuing anti-aging initiatives and is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. (www.neostem.com) Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.
